期刊
EUROPEAN CELLS & MATERIALS
卷 24, 期 -, 页码 118-135出版社
AO RESEARCH INSTITUTE DAVOS-ARI
DOI: 10.22203/eCM.v024a09
关键词
Hypertrophy; mesenchymal stem cells; chondrogenesis; biomaterials; epigenetics; hypoxia; coculture
资金
- Swiss National Science Foundation [CR23I2-130678/1]
- European Union [NMP4-SL-2009-229292]
- Swiss National Science Foundation (SNF) [CR23I2_130678] Funding Source: Swiss National Science Foundation (SNF)
Chondrocyte hypertrophy is one of the key physiological processes involved in the longitudinal growth of long bones, yet regulation of hypertrophy is becoming increasingly relevant for clinical application of mesenchymal stem cells (MSCs) and screening for drugs to treat hypertrophic osteoarthritis. The extraordinary cell volume increase during hypertrophy is accompanied by an up-regulation of collagen X, matrix metalloproteinases (MMPs), and vascular endothelial growth factor (VEGF), all which are targets of the runt-related transcription factor 2 (Runx2). Many pathways, including parathyroid hormone-related protein (PTHrP)/Indian Hedgehog, Wingless/Int (Wnt)/beta-catenin, and transforming growth factor beta (TGF-beta)/Sma and Mad Related Family (Smad) pathways, can regulate hypertrophy, but factors as diverse as hypoxia, co-culture, epigenetics and biomaterial composition can also potently affect Runx2 expression. Control of hypertrophic differentiation can be exploited both for cartilage repair, where a stable phenotype is desired, but also in bone regeneration, where hypertrophic cartilage could act as a template for endochondral bone formation. We hope this review will motivate the design of novel engineered microenvironments for skeletal regeneration applications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据